Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers

Journal of Virology

Volumn 79, Issue 8, 2005, Pages 5116-5128

  Kinney, Richard M ^a   Huang, Claire Y H ^a   Rose, Becky C ^a   Kroeker, Andrew D ^b   Dreher, Theo W ^c   Iversen, Patrick L ^b   Stein, David A ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b AVI BIOPHARMA INC   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEOTIDE; OLIGOMER; PEPTIDE DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIZATION; DENGUE; DENGUE VIRUS; DRUG ACTIVITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; DRUG SPECIFICITY; DRUG TARGETING; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GROWTH CURVE; INCUBATION TIME; MONKEY; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; SEROTYPE; TRANSLATION INITIATION; VERO CELL; VIROGENESIS; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TITRATION; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIVIRAL AGENTS; BASE SEQUENCE; CERCOPITHECUS AETHIOPS; DENGUE VIRUS; KINETICS; MORPHOLINES; OLIGODEOXYRIBONUCLEOTIDES; VERO CELLS;

EID: 16244366477     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.79.8.5116-5128.2005     Document Type: Article

References (46)

1. Brinton, M. A., and J. H. Dispoto. 1988. Sequence and secondary structure analysis of the 5′-terminal region of flavivirus genome RNA. Virology 162:290-299.
2. Butrapet, S., C. Y. Huang, D. J. Pierro, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2000. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74:3011-3019.
3. Cahour, A., A. Pletnev, M. Vazielle-Falcoz, L. Rosen, and C. J. Lai. 1995. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207:68-76.
4. Dias, N., and C. A. Stein. 2002. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1:347-355.
5. Garcia-Montalvo, B. M., F. Medina, and R. M. del Angel. 2004. La protein binds to NS5 and NS3 and to the 5′ and 3′ ends of dengue 4 virus RNA. Virus Res. 102:141-150.
6. Ghosh, C., D. Stein, D. Weller, and P. Iversen. 2000. Evaluation of antisense mechanisms of action. Methods Enzymol. 313:135-143.
7. Gubler, D. J. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-496.
8. Gubler, D. J. 2002. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 10:100-103.
9. Hahn, C. S., Y. S. Hahn, C. M. Rice, E. Lee, L. Dalgarno, E. G. Strauss, and J. H. Strauss. 1987. Conserved elements in the 3' untranslated region of flavivirus RNAs and potential cyclization sequences. J. Mol. Biol. 198:33-41.
10. Halstead, S. B. 1988. Pathogenesis of dengue: challenges to molecular biology. Science 239:476-481.
11. Hudziak, R. M., E. Barofsky, D. F. Barofsky, D. L. Weller, S. B. Huang, and D. D. Weller. 1996. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6:267-272.
12. Irie, K., P. M. Mohan, Y. Sasaguri, R. Putnak, and R. Padmanabhan. 1989. Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene 75:197-211.
13. Iversen, P. L., V. Arora, A. J. Acker, D. H. Mason, and G. R. Devi. 2003. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a phase I salety study in humans. Clin. Cancer Res. 9:2510-2519.
14. Khromykh, A. A., N. Kondratieva, J. Y. Sgro, A. Palmenberg, and E. G. Westaway. 2003. Significance in replication of the terminal nucleotides of the flavivirus genome. J. Virol. 77:10623-10629.
15. Khromykh, A. A., H. Meka, K. J. Guyatt, and E. G. Westaway. 2001. Essential role of cyclization sequences in flavivirus RNA replication. J. Virol. 75:6719-6728.
16. Kinney, R. M., S. Butrapet, G. J. Chang, K. R. Tsuchiya, J. T. Roehrig, N. Bhamarapravati, and D. J. Gubler. 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300-308.
17. Kipshidze, N., J. Moses, L. R. Shankar, and M. Leon. 2001. Perspectives on antisense therapy for the prevention of restenosis. Curr. Opin. Mol. Ther. 3:265-277.
18. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
19. Leitmeyer, K. C., D. W. Vaughn, D. M. Watts, R. Salas, I. Villalobos, de Chacon, C. Ramos, and R. Rico-Hesse. 1999. Dengue virus structural differences that correlate with pathogenesis. J. Virol. 73:4738-4747.
20. Leyssen, P., N. Charlier, J. Paeshuyse, E. De Clercq, and J. Neyts. 2003. Prospects for antiviral therapy. Adv. Virus Res. 61:511-553.
21. Lindenbach, B. D., and C. M. Rice. 2003. Molecular biology of flaviviruses. Adv. Virus Res. 59:23-61.
22. Lo, M. K., M. Tilgner, K. A. Bernard, and P. Y. Shi. 2003. Functional analysis of mosquito-borne flavivirus conserved sequence elements within 3′ untranslated region of West Nile virus by use of a reporting replicon that differentiates between viral translation and RNA replication. J. Virol. 77:10004-10014.
23. Ma, D. D., T. Rede, N. A. Naqvi, and P. D. Cook. 2000. Synthetic oligonucleotides as therapeutics: the coming of age. Biotechnol. Annu. Rev. 5:155-196.
24. Markoff, L. 2003. 5′- and 3′-noncoding regions in flavivirus RNA. Adv. Virus Res. 59:177-228.
25. Marwick, C. 1998. First "antisense" drug will treat CMV retinitis. JAMA 280:871.
26. Miller, B. R., and C. J. Mitchell. 1986. Passage of yellow fever virus: its effect on infection and transmission rates in Aedes aegypti. Am. J. Trop. Med. Hyg. 35:1302-1309.
27. Mongkolsapaya, J., W. Dejnirattisai, X. N. Xu, S. Vasanawathana, N. Tangthawornchaikul, A. Chairunsri, S. Sawasdivorn, T. Duangchinda, T. Dong, S. Rowland-Jones, P. T. Yenchitsomanus, A. McMichael, P. Malasit, and G. Screaton. 2003. Original antigenic sin and apoptosis in the patho′ genesis of dengue hemorrhagic fever. Nat. Med. 9:921-927.
28. Moulton, H. M., M. H. Nelson, S. A. Hatlevig, M. T. Reddy, and P. L. Iversen. 2004. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug. Chem. 15:290-299.
29. Nasevicius, A., and S. C. Ekker. 2000. Effective targeted gene 'knockdown' in zebrafish. Nat. Genet. 26:216-220.
30. Neuman, B. W., D. A. Stein, A. D. Kroeker, A. D. Paulino, H. M. Moulton, P. L. Iversen, and M. J. Buchmeier. 2004. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth. J. Virol. 78:5891-5899.
31. Pandey, B. D., and A. Igarashi. 2000. Severity-related molecular differences among nineteen strains of dengue type 2 viruses. Microbiol. Immunol. 44:179-188.
32. Pestova, T. V., V. G. Kolupaeva, I. B. Lomakin, E. V. Pilipenko, I. N. Shatsky, V. I. Agol, and C. U. Hellen. 2001. Molecular mechanisms of translation initiation in eukaryotes. Proc. Natl. Acad. Sci. USA 98:7029-7036.
33. Proutski, V., E. A. Gould, and E. C. Holmes. 1997. Secondary structure of the 3′ untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res. 25:1194-1202.
34. Proutski, V., T. S. Gritsun, E. A. Gould, and E. C. Holmes. 1999. Biological consequences of deletions within the 3′-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res. 64:107-123.
35. Rauscher, S., C. Flamm, C. W. Mandl, F. X. Heinz, and P. F. Stadler. 1997. Secondary structure of the 3′-noncoding region of flavivirus genomes: comparative analysis of base pairing probabilities. RNA 3:779-791.
36. Raviprakash, K., K. Liu, M. Matteucci, R. Wagner, R. Riffenburgh, and M. Carl. 1995. Inhibition of dengue virus by novel, modified antisense oligonucleotides. J. Virol. 69:69-74.
37. Shi, P. Y., M. A. Brinton, J. M. Veal, Y. Y. Zhong, and W. D. Wilson. 1996. Evidence for the existence of a pseudoknot structure at the 3′ terminus of the flavivirus genomic RNA. Biochemistry 35:4222-4230.
38. Stein, D., E. Foster, S. B. Huang, D. Weller, and J. Summerton. 1997. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7:151-157.
39. Stein, D. A., D. E. Skilling, P. L. Iversen, and A. W. Smith. 2001. Inhibition of vesivirus infections in mammalian tissue culture with antisense morpholino oligomers. Antisense Nucleic Acid Drug Dev. 11:317-325.
40. Summerton, J. 1999. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim. Biophys. Acta 1489:141-158.
41. Summerton, J., and D. Weller. 1997. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7:187-195.
42. Thurner, C., C. Witwer, I. L. Hofacker, and P. F. Stadler. 2004. Conserved RNA secondary structures in Flaviviridae genomes. J. Gen. Virol. 85:1113-1124.
43. Tilgner, M., and P. Y. Shi. 2004. Structure and function of the 3′ terminal six nucieotides of the West Nile virus genome in viral replication. J. Virol. 78:8159-8171.
44. You, S., B. Falgout, L. Markoff, and R. Padmanabhan. 2001. In vitro RNA synthesis from exogenous dengue viral RNA templates requires long range interactions between 5′- and S′-terminal regions that influence RNA structure. J. Biol. Chem. 276:15581-15591.
45. You, S., and R. Padmanabhan. 1999. A novel in vitro replication system for dengue virus. Initiation of RNA synthesis at the 3′-end of exogenous viral RNA templates requires 5′- and 3′-terminal complementary sequence motifs of the viral RNA. J. Biol. Chem. 274:33714-33722.
46. Zeng, L., B. Falgout, and L. Markoff. 1998. Identification of specific nucleotide sequences within the conserved 3′-SL in the dengue type 2 virus genome required for replication. J. Virol. 72:7510-7522.